開拓藥業-B(9939.HK)納入MSCI中國指數,盤中漲超17%
格隆匯5月13日丨全球知名指數公司MSCI今日公佈了全球小型股指數(MSCI GLOBAL SMALL CAP INDEXES)半年度審核變更結果,預計5月31日收盤後正式生效。MSCI中國指數的調整往往吸引大量海外被動資金,其中的出入名單因此備受關注。其中,開拓藥業-B(9939.HK)受納入MSCI中國指數(MSCI CHINA INDEX) 名單利好影響,盤中漲幅一度超17%。此前,開拓藥業在4月6日公佈了普克魯胺治療輕中症的III期全球多中心臨牀試驗最終關鍵結果。數據顯示,普克魯胺有效降低新冠患者(主要受Delta和Omicron變異株感染)的住院/死亡率,特別是對於服藥超過7天的全部患者,以及伴有高風險因素的中高年齡新冠患者達到100%保護率,具有統計學顯著性。同時,普克魯胺可以顯著降低新冠病毒載量,改善相關新冠症狀。普克魯胺用藥的安全性也進一步得到驗證(適用於18歲以上成年男女)。公司正在積極推進向中國、美國及其他國家和地區的國家藥物監督機構申請緊急用藥EUA許可。此次開拓藥業進入MSCI中國指數名單,充分體現出國際資本市場對公司研發實力和創新潛力的高度認可,未來有望迎來更多資金的流入,提高公司股票買賣的流動性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.